RENOVUE-DIP
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Jul 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RENOVUE-DIP is an injectable diagnostic or therapeutic agent approved in 1978 by Bracco, an established pharmaceutical and diagnostic imaging company. The specific mechanism of action and clinical indications are not publicly detailed in available data, limiting characterization of its therapeutic role.
LOE Approaching
As a near-LOE product with 30% competitive pressure and minimal market data available, commercial teams face declining revenue and likely organizational contraction.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
RENOVUE-DIP represents a mature, legacy product with zero linked job openings and approaching loss of exclusivity, indicating limited career growth and potential downsizing in the coming years. Professionals considering roles on this product should expect defensive market strategies and potential portfolio rationalization.
Brand ManagerField Sales Representative
Worked on RENOVUE-DIP at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.